MedTrace Logo

STAAR Visian Toric ICL Post-Approval Study

NCT04516772 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2026-03-13

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the long term (i.e. 24 months) clinical performance of the Visian® Toric Implantable Collamer® Lens (ICL).

Conditions

  • Myopic Astigmatism

Interventions

DEVICE

Visian TICL

The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.

Sponsors & Collaborators

  • Staar Surgical Company

    lead INDUSTRY

Principal Investigators

  • Joanne Egamino, PhD · VP, Clinical Affairs

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-21
Primary Completion
2024-12-11
Completion
2024-12-11
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04516772 on ClinicalTrials.gov